Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy.
The price of so-called non-human primates in China — an indicator of the future pipeline of drugs undergoing clinical trials — hit a peak of $26,000 per animal in 2022, up from $4,000 in 2019. But by the end of last year, it had fallen to $11,000, according to UBS data.
The first two years of the Covid-19 pandemic saw “booming investment” in drug development, said UBS China healthcare analyst Chen Chen, as investors piled money into backing domestic vaccine candidates and other drug development.
您已阅读18%（669字），剩余82%（3138字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。